CClinicalTrials.gg
TerminatedNCT02861911NEMS and FSHDUpdated May 9, 2019

Effects of NMES on Muscle Function of Patients With FSHD: a Double-blind Randomized Controled Clinical Trial

An interventional study of Current flow between sensory and motor threshold and Current intensity upper of motor threshold by Kneehab XP technology in Primary Disease Facioscapulohumeral Dystrophy (FSHD), sponsored by University Hospital, Montpellier. Terminated at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-05-09.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Supportive care

Why this study was terminated
Difficulty in recruiting patients

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Oct 2015, registered Aug 2016).
Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disease characterized by progressive weakness and atrophy of specific skeletal muscles. One of the major problems of patients affected by FSHD is the limitation in performing daily activities induced by the progressive muscle weakness. This sedentary lifestyle can cause a "debilitative cycle," and neuromuscular deconditioning can even aggravate the muscular deficiencies. Recent studies have indicated the safety and the effectiveness of moderate aerobic training programs in patients with FSHD. However, these training programs have limited applicability in patients with more severe muscular weakness. Artificial strength training by means of neuromuscular electrical stimulation (NMES) appears to be a promising rehabilitation strategy for FSHD patients suffering from neuromuscular disorders. Therefore we propose to investigate the feasibility, safety, and effectiveness of NMES strength training to counteract quadriceps muscle weakness in patients affected by FSHD.

Read the detailed description

NMES will be delivered to both quadriceps by means of a Kneehab® XP device, which is an innovative and clinically-proven garment-based product designed specifically to treat quadriceps muscle atrophy. The main NMES current parameters are: 50-Hz frequency, 100-400 µs pulse duration, 5:10-second on:off time. Each session will last approximately 20 minutes and will be repeated 5 days/week for a total duration of the treatment program of 3 months.

02

Conditions studied

  • Primary Disease Facioscapulohumeral Dystrophy (FSHD)

Keywords

  • Muscle function
  • Oxidative stress
  • Quality of life
  • Physical activities
03

In context

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Molecular and/or clinical diagnosis for FSHD
  • Vignos scale ≤ 5: Able to walk without help
  • Clinically characterized by quadriceps muscle weakness but with a maximal voluntary contraction (MVC) between 8 and 16 Kg
  • Follow as part of their usual care in the Clinical Physiology Department of the University Hospital of Montpellier
  • Free and informed consent of the patient
  • Patient affiliated or beneficiary of a social security system

Exclusion criteria

Exclusion Criteria:

  • Patient with co-morbidity:pathologies heart, pathologies respiratory, metabolic and endocrine -pathologies, pathologies cancer.
  • Patients treated with drugs could cause muscle side effects or interfere with muscle metabolism.
  • Lesions or skin inflammation at the thighs that can prevent the application of NMES
  • Claustrophobic subject
  • Carrier of intracranial vascular clip, cardiac pacemaker, neurostimulator, cochlear implant, or intraocular metallic foreign
  • Pregnant or nursing women
  • Vulnerable Persons and protected Major or unable to consent
  • Patient in exclusion period relative over another protocol, or for which the annual amount of maximum compensation of € 4,500 has been reached
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
9 participants (actual)

Study arms

  • Sham comparator
    Control group

    The current intensity is generally defined between the sensory and motor threshold (patients feel the power but no visible muscle contraction will be obtained).

    Other: Current flow between sensory and motor threshold

  • Active comparator
    Active NMES group

    Tthe current intensity must always meet and exceed the motor threshold (patients feel the current and quadriceps muscle will contract a visible and quantifiable if possible).

    Device: Current intensity upper of motor threshold by Kneehab XP technology

Interventions

  • OtherCurrent flow between sensory and motor threshold

    Artificial strength training by means of neuromuscular electrical stimulation (NMES)

  • DeviceCurrent intensity upper of motor threshold by Kneehab XP technology

    Artificial strength training by means of neuromuscular electrical stimulation (NMES)

06

What researchers measure

Primary outcomes

  1. Maximal voluntary contraction (MVC) strength of the quadriceps

    Time frame: At 3 months

Secondary outcomes

  1. Effect of NEMS on the quality of life (SF36 questionnaire)

    Time frame: At 3 months

  2. Effect of NMES on the quadriceps endurance evaluated in a dynamic test against a charge equal to 30% of maximal isometric force.

    Time frame: At 3 months

  3. Evaluation of the body composition by bioelectric impedance analysis (BIA) after NMES effect

    Time frame: At 3 months

  4. Effect of NMES on the bone mineral density by dual energy X-ray absorptiometry (DEXA)

    Time frame: At 3 months

  5. Effect of NMES on the oxidative stress markers in blood and urine by blood and urine tests

    Time frame: At 3 months

07

Study locations

1 site
  • Montpellier University Hospital
    Montpellier, 34295, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02861911
Lead sponsor
University Hospital, Montpellier
Responsible party
Sponsor
First posted
Aug 10, 2016
Start date
Oct 20, 2015
Primary completion
Sep 13, 2016
Completion
Jul 2018
Last update
May 9, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion